Free Trial

Atea Pharmaceuticals (AVIR) Competitors

Atea Pharmaceuticals logo
$3.06 -0.06 (-1.92%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$3.06 +0.00 (+0.16%)
As of 10/17/2025 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AVIR vs. CRMD, ANAB, PHAT, TNGX, AVXL, PRME, IOVA, ABUS, XNCR, and KURA

Should you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include CorMedix (CRMD), AnaptysBio (ANAB), Phathom Pharmaceuticals (PHAT), Tango Therapeutics (TNGX), Anavex Life Sciences (AVXL), Prime Medicine (PRME), Iovance Biotherapeutics (IOVA), Arbutus Biopharma (ABUS), Xencor (XNCR), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry.

Atea Pharmaceuticals vs. Its Competitors

CorMedix (NASDAQ:CRMD) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

CorMedix has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.

CorMedix has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CorMedix$43.47M18.28-$17.93M$0.7513.57
Atea PharmaceuticalsN/AN/A-$168.38M-$1.61-1.90

34.2% of CorMedix shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 5.3% of CorMedix shares are held by insiders. Comparatively, 18.1% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, CorMedix had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 1 mentions for CorMedix and 0 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.00 beat CorMedix's score of -0.07 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
CorMedix Neutral
Atea Pharmaceuticals Neutral

CorMedix has a net margin of 42.11% compared to Atea Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 42.73% beat Atea Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CorMedix42.11% 42.73% 34.19%
Atea Pharmaceuticals N/A -32.55%-30.47%

CorMedix presently has a consensus price target of $18.00, indicating a potential upside of 76.82%. Atea Pharmaceuticals has a consensus price target of $6.00, indicating a potential upside of 96.08%. Given Atea Pharmaceuticals' higher probable upside, analysts plainly believe Atea Pharmaceuticals is more favorable than CorMedix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CorMedix
0 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.70
Atea Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

CorMedix beats Atea Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Atea Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVIR vs. The Competition

MetricAtea PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$242.84M$3.44B$6.19B$10.56B
Dividend YieldN/A2.27%5.70%4.81%
P/E Ratio-1.9023.0185.5427.13
Price / SalesN/A481.75608.39130.24
Price / CashN/A46.9237.1060.81
Price / Book0.5910.4112.236.52
Net Income-$168.38M-$52.77M$3.33B$276.93M
7 Day Performance-2.55%2.31%1.17%1.93%
1 Month Performance6.25%12.59%6.85%2.19%
1 Year Performance-19.90%11.18%58.93%34.62%

Atea Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVIR
Atea Pharmaceuticals
1.8063 of 5 stars
$3.06
-1.9%
$6.00
+96.1%
-19.9%$242.84MN/A-1.9070
CRMD
CorMedix
3.282 of 5 stars
$11.56
+1.9%
$18.00
+55.7%
-7.5%$885.19M$43.47M15.4130
ANAB
AnaptysBio
2.8554 of 5 stars
$30.25
-2.2%
$48.75
+61.2%
-1.0%$866.23M$123.16M-6.75100Trending News
Analyst Forecast
Analyst Revision
PHAT
Phathom Pharmaceuticals
2.9641 of 5 stars
$11.61
-4.9%
$17.50
+50.7%
-19.4%$866.22M$55.25M-2.45110News Coverage
Analyst Upgrade
TNGX
Tango Therapeutics
1.5388 of 5 stars
$7.58
-2.3%
$10.50
+38.5%
+21.0%$863.38M$42.07M-5.7090
AVXL
Anavex Life Sciences
3.1774 of 5 stars
$9.61
-3.5%
$44.00
+357.9%
+58.9%$855.50MN/A-16.8640
PRME
Prime Medicine
0.703 of 5 stars
$6.08
-3.8%
N/AN/A$850.51M$2.98M-3.90N/AGap Down
IOVA
Iovance Biotherapeutics
4.2705 of 5 stars
$2.21
-5.6%
$11.90
+438.5%
-78.7%$846.74M$241.53M-1.80500News Coverage
Gap Down
ABUS
Arbutus Biopharma
2.1481 of 5 stars
$4.34
-0.9%
$5.00
+15.2%
+6.3%$839.64M$15.42M-14.9790News Coverage
XNCR
Xencor
3.7061 of 5 stars
$11.79
+0.2%
$24.22
+105.4%
-32.2%$839.47M$146.93M-4.91280News Coverage
Analyst Forecast
KURA
Kura Oncology
4.1507 of 5 stars
$9.80
+2.4%
$24.10
+145.9%
-45.3%$830.65M$83.28M-4.34130Gap Down

Related Companies and Tools


This page (NASDAQ:AVIR) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners